Current Data from the first Head-to-Head Study on Biologic Therapy in Ulcerative Colitis Patients Clinical Remission and Mucosal Healing in Adults: Vedolizumab superior to Adalimumab

被引：0
|
作者：
Thaesler, Elke
机构：
来源：
VISCERAL MEDICINE | 2019年 / 35卷 / 04期
关键词：
MAINTENANCE THERAPY; INDUCTION; DISEASE;
D O I：
10.1159/000502370
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：275 / 275
页数：1
相关论文
共 50 条
  • [41] Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study
    Tursi, Antonio
    Mocci, Giammarco
    Cingolani, Linda
    Savarino, Edoardo
    Pica, Roberta
    Cocco, Andrea
    Zippi, Maddalena
    Napolitano, Daniele
    Schiavoni, Elisa
    Pugliese, Daniela
    Scaldaferri, Franco
    Costa, Francesco
    Marzo, Manuela
    Serio, Mariaelena
    Scarcelli, Antonella
    Bolognini, Laura
    Bendia, Emanuele
    Maconi, Giovanni
    Cannatelli, Rosanna
    Piergallini, Simona
    Bodini, Giorgia
    Calabrese, Francesco
    Ferronato, Antonio
    Pranzo, Giuseppe
    Elisei, Walter
    Monterubbianesi, Rita
    Faggiani, Roberto
    Rodino, Stefano
    Sebkova, Ladislava
    Grossi, Laurino
    Gaiani, Federica
    de Angelis, Gianluigi
    Lorenzetti, Roberto
    Allegretta, Leonardo
    Cazzato, Alessia Immacolata
    Scorza, Stefano
    Della Valle, Nicola
    Sacco, Rodolfo
    Forti, Giacomo
    Colucci, Raffaele
    Tonti, Paolo
    Neve, Viviana
    Rocco, Giulia
    Sacchi, Carlotta
    Zampaletta, Costantino
    Pagnini, Cristiano
    Graziani, Maria Giovanna
    Di Paolo, Maria Carla
    Onidi, Francesca Maria
    Satta, Paolo Usai
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (14) : 1649 - 1656
  • [42] A study level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors (EGFRIs) vs bevacizumab in patients with metastatic colorectal cancer (mCRC)
    Heinemann, V.
    Rivera, F.
    O'Neill, B.
    Koukakis, R.
    Terwey, J. H.
    Douillard, J. Y.
    ANNALS OF ONCOLOGY, 2015, 26
  • [43] No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials (vol 113, pg 1197, 2018)
    Singh, Siddharth
    Proudfoot, James
    Dulai, Parambir S.
    Jairath, Vipul
    Fumery, Mathurin
    Xu, Ronghui
    Feagan, Brian G.
    Sandborn, William J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 (06): : 1010 - 1010
  • [44] Evaluation of drug-utilization and healthcare facilities use in patients with ulcerative colitis and treated with biologic therapy using data of an Italian healthcare administrative database: Results from michelangelo study
    Ferraro, Sara
    Paoletti, Olga
    Giometto, Sabrina
    Tillati, Silvia
    Convertino, Irma
    Valdiserra, Giulia
    Cappello, Emiliano
    Bonaso, Marco
    Bartolini, Claudia C.
    Lorenzoni, Valentina
    Turchetti, Giuseppe
    Gini, Rosa
    Fornai, Matteo
    Lucenteforte, Ersilia
    Tuccori, Marco
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 363 - 363
  • [45] The Effect of HLA-DRB1 Risk Alleles (Shared Epitope) on Changes in Immune Cell Subsets and Disease Activity Following Treatment with Abatacept versus Adalimumab in Seropositive Biologic-Naive Patients with Early, Moderate-to-Severe RA: Data from a Head-to-Head Single-Blinded Trial
    Buckner, Jane
    Bykerk, Vivian
    Holers, V. Michael
    Bridges, S. Louis
    Rigby, William
    Gao, Sheng
    Nys, Marleen
    Ray, Neelanjana
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [46] A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer
    Heinemann, Volker
    Rivera, Fernando
    O'Neil, Bert H.
    Stintzing, Sebastian
    Koukakis, Reija
    Terwey, Jan-Henrik
    Douillard, Jean-Yves
    EUROPEAN JOURNAL OF CANCER, 2016, 67 : 11 - 20
  • [47] Persistence of bowel urgency despite clinical remission after induction therapy is associated with unfavorable long-term outcomes in patients with ulcerative colitis: results from the multicenter UCRGENCY study.
    Buisson, A.
    Amiot, A.
    Nachury, M.
    Altwegg, R.
    Serrero, M.
    Guilmoteau, T.
    Treton, X.
    Caillo, L.
    Vuitton, L.
    Bouguen, G.
    Pereira, B.
    Fumery, M.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I804 - I804
  • [48] Adsorptive Depletion of Myeloid Lineage Leucocytes as Remission Induction Therapy in Patients with Ulcerative Colitis after Failure of First-Line Medications: Results from a Three-Year Real World, Clinical Practice
    Iida, Takayuki
    Ikeya, Kentaro
    Kato, Masaichi
    Abe, Jinro
    Yamamoto, Masayoshi
    Watanabe, Fumitoshi
    Sugimoto, Ken
    Hanai, Hiroyuki
    DIGESTION, 2017, 96 (02) : 119 - 126
  • [49] EFFICACY AND SAFETY OF OPEN-LABEL TREATMENT WITH TOFACITINIB 10 MG TWICE DAILY IN PATIENTS WITH ULCERATIVE COLITIS WITH CLINICAL RESPONSE, BUT NOT REMISSION, AFTER 52 WEEKS OF MAINTENANCE THERAPY: DATA FROM THE OCTAVE STUDIES
    Chiorean, Michael V.
    Su, Chinyu
    Matsuoka, Katsuyoshi
    Orlando, Ambrogio
    Thorpe, Andrew J.
    Nduaka, Chudy I.
    Chapman, Douglass S.
    Woodworth, Deborah A.
    Lawendy, Nervin
    Friedman, Gary S.
    Cohen, Russell D.
    GASTROENTEROLOGY, 2019, 156 (06) : S169 - S170
  • [50] Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies
    Chiorean, M.
    Su, C.
    Matsuoka, K.
    Orlando, A.
    Thorpe, A. J.
    Nduaka, C. I.
    Chapman, D. S.
    Woodworth, D. A.
    Lawendy, N.
    Friedman, G. S.
    Cohen, R. D.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S50 - S50
12345